India and Europe Generic Injectable Market - Industry Trends and Forecast to 2035

List of Tables

The Europe generic injectable market is expected to reach USD 99,764.84 million by 2035 from USD 36,370.78 million in 2023, growing with a CAGR of 9.0% in the forecast period of 2024 to 2035.

The India generic injectable market is expected to reach USD 19,298.93 million by 2035 from USD 7,128.62 million in 2023, growing with a CAGR of 8.9% in the forecast period of 2024 to 2035.

Market Segmentation

India and Europe Generic Injectable Market, By Therapeutic Application (Oncology, Cardiovascular Disorders, Infectious Diseases, Pain Management, Metabolic Disorders (Diabetes) Immunology Disorders), Biosimilar Drugs (Semaglutide, Ibutidlide Fumarate, Evolocumab, Alirocumab, Anidulafungin, Dulaglutide, Lixisenatide, Exenatide, Liraglutide, and Adalimumab), End User (Direct Sale, Distributors, Pharmaceutical Wholesalers, Drug Stores, Pharmacy, Group Purchasing Organizations(GPOs), and Others), Distribution Channel (Contract Manufacturers, Pharmaceutical Wholesalers, Pharmacy Chains, Group Purchasing Organizations(GPOs), and Others) Country (India) - Industry Trends and Forecast to 2035.

Overview of India and Europe Generic Injectable Market Dynamics

Driver
Surge in the development and production of generic injectable
Restraint
Ensuring the qualification and ethical standards of a Contract Manufacturing Organization (CMO)
Opportunity
Market expansion surging with a heightened focus on contract research manufacturing organization

Market Players

Some of the major market players operating in the India and Europe generic injectable market are listed below:

Fresenius SE & Co. KGaA
Amneal Pharmaceuticals LLC
Sun Pharmaceutical Industries Ltd.
LUPIN.
Zydus Group
Aurobindo Pharma.
Cipla Inc.
Concord Biotech.
Dr. Reddy's Laboratories Ltd.
Gland Pharma Limited
GLENMARK PHARMACEUTICALS LTD.
Hikma Pharmaceticals PLC
Intas Pharmaceuticals Ltd.
Par Pharmacetical
Sandoz Group AG
Sanofi
Viatris Inc.

1 INTRODUCTION 15

1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF INDIA AND EUROPE GENERIC INJECTABLE MARKET 15
1.4 LIMITATIONS 16
1.5 MARKETS COVERED 16

2 MARKET SEGMENTATION 19

2.1 MARKETS COVERED 19
2.2 YEARS CONSIDERED FOR THE STUDY 20
2.3 CURRENCY AND PRICING 20
2.4 DBMR TRIPOD DATA VALIDATION MODEL 21
2.5 INDIA MULTIVARIATE MODELLING 25
2.6 TYPE LIFELINE CURVE 27
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.8 VENDOR SHARE ANALYSIS 29
2.9 SECONDARY SOURCES 30
2.10 ASSUMPTIONS 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 33

4.1 PESTAL ANALYSIS 35
- 4.1.1 EUROPE 35
- 4.1.2 INDIA 36
4.2 PORTER FIVE FORCED 37
- 4.2.1 EUROPE 37
- 4.2.2 INDIA 38
4.3 EPIDEMIOLOGY 39

5 EUROPE GENERIC INJECATBLE MARKET OVERVIEW 41

5.1 DRIVERS 43
- 5.1.1 SURGE IN DEVELOPMENT AND PRODUCTION OF GENERIC INJECTABLE 43
- 5.1.2 PIONEERING PROGRESS FUELED BY TECHNOLOGICAL ADVANCEMENTS IN DRUG MOLECULES 44
- 5.1.3 SURGE OF GENERIC INJECTABLE MARKET AMIDST THE ESCALATING PREVALENCE OF CHRONIC DISEASES 44
5.2 RESTRAINTS 46
- 5.2.1 ENSURING AND MAINTAINING HIGH-QUALITY STANDARDS 46
- 5.2.2 ENSURING THE QUALIFICATION AND ETHICAL STANDARDS OF A CONTRACT MANUFACTURING ORGANIZATION (CMO) 46
- 5.2.3 NAVIGATING MARKET CHALLENGES IN THE DEVELOPMENT COSTS OF GENERIC INJECTABLE 48
5.3 OPPORTUNITIES 48
- 5.3.1 ASCENDANCE OF MARKET GROWTH THROUGH INCREASED EMPHASIS ON CONTRACT RESEARCH MANUFACTURING 48
- 5.3.2 SYNERGIZING INNOVATION THROUGH COLLABORATIVE DRUG RESEARCH AND DEVELOPMENT 49
- 5.3.3 EXPANSION IN MARKET GROWTH FUELED BY RISING PREFERENCE FOR GENERIC DRUGS OVER NOVEL ALTERNATIVES 50
- 5.3.4 EXPANDING HORIZONS PROPELLED BY GROWING PIPELINE OF INNOVATIVE PRODUCTS 51
5.4 CHALLENGES 52
- 5.4.1 LOGISTICAL CHALLENGES DUE TO SPECIALIZED STORAGE AND TRANSPORTATION NEEDS 52

6 INDIA GENERIC INJECATBLE MARKET OVERVIEW 53

6.1 DRIVERS 55
- 6.1.1 ESCALATING INCIDENCE OF CHRONIC DISEASES 55
- 6.1.2 DEPENDENCE ON THE INDIAN MANUFACTURERS FOR GENERIC VERSION 55
- 6.1.3 AVAILABILITY OF A WIDE VARIETY OF DISTRIBUTION CHANNELS 57
6.2 RESTRAINTS 58
- 6.2.1 ELEVATED STANDARDS OF QUALITY ASSURANCE IN GENERIC INJECTABLE 58
6.3 OPPORTUNITIES 58
- 6.3.1 MARKET EXPANSION SURGING WITH A HEIGHTENED FOCUS ON CONTRACT RESEARCH MANUFACTURING ORGANIZATION 58
- 6.3.2 HARMONIZING INNOVATION BY COLLABORATIVE EFFORTS IN DRUG RESEARCH AND DEVELOPMENT 59
- 6.3.3 MARKET GROWTH EXPANDS DUE TO INCREASING FAVOR FOR GENERIC DRUGS INSTEAD OF NOVEL ALTERNATIVES 60
- 6.3.4 GOVERNMENT DRIVE AND ADVOCACY FOR GENERIC MEDICATIONS 61
6.4 CHALLENGES 61
- 6.4.1 CHALLENGES IN LOGISTICS ARISING FROM SPECIALIZED STORAGE AND TRANSPORTATION REQUIREMENTS 61

7 INDIA & EUROPE INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION 63

7.1 OVERVIEW 64
7.2 ONCOLOGY 70
7.3 CARDIOVASCULAR DISORDERS 71
7.4 INFECTIOUS DISEASES 73
7.5 PAIN MANAGEMENT 75
7.6 METABOLIC DISORDERS (DIABETES) 76
7.7 IMMUNOLOGY DISORDERS 77

8 INDIA & EUROPE INJECTABLE DRUG DELIVERY MARKET, BY BIOSIMILAR DRUGS 78

8.1 OVERVIEW 79
8.2 SEMAGLUTIDE 84
8.3 IBUTILIDE FUMARATE 84
8.4 EVOLOCUMAB 84
8.5 ALIROCUMAB 84
8.6 ANIDULAFUNGIN 84
8.7 DULAGLUTIDE 84
8.8 LIXISENATIDE 84
8.9 EXENATIDE 85
8.10 LIRAGLUTIDE 85
8.11 ADALIMUMAB 85

9 INDIA & EUROPE INJECTABLE DRUG DELIVERY MARKET, BY END USER 86

9.1 OVERVIEW 87
9.2 DIRECT SALES DISTRIBUTORS 94
9.3 PHARMACEUTICAL WHOLESALERS 94
9.4 DRUG STORES 94
9.5 PHARMACY 95
9.6 GROUP PURCHASING ORGANIZATIONS (GPOS) 95
9.7 OTHERS 95

10 INDIA & EUROPE INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 96

10.1 OVERVIEW 97
10.2 CONTRACT MANUFACTURERS 104
10.3 PHARMACEUTICAL WHOLESALERS 104
10.4 PHARMACY CHAINS 104
10.5 GROUP PURCHASING ORGANIZATIONS (GPOS) 104
10.6 OTHERS 104

11 INDIA AND EUROPE GENERIC INJECTABLE MARKET: COMPANY LANDSCAPE 105

11.1 COMPANY SHARE ANALYSIS: EUROPE 105
11.2 COMPANY SHARE ANALYSIS: INDIA 106

12 SWOT ANALYSIS 107

12.1 CONTRACT MANUFACTURERS 107
12.2 MANUFACTURERS 108
12.3 DISTRIBUTORS 109

13 COMPANY PROFILE (CONTRACT MANUFACTURERS) 110

13.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 110
- 13.1.1 COMPANY SNAPSHOT 110
- 13.1.2 PRODUCT PORTFOLIO 110
- 13.1.3 RECENT DEVELOPMENT 110
13.2 CARDINAL HEALTH 111
- 13.2.1 COMPANY SNAPSHOT 111
- 13.2.2 REVENUE ANALYSIS 111
- 13.2.3 PRODUCT PORTFOLIO 112
- 13.2.4 RECENT DEVELOPMENT 112
13.3 DIVI'S LABORATORIES LIMITED. 113
- 13.3.1 COMPANY SNAPSHOT 113
- 13.3.2 REVENUE ANALYSIS 113
- 13.3.3 PRODUCT PORTFOLIO 114
- 13.3.4 RECENT DEVELOPMENT 114
13.4 DR. REDDY'S LABORATORIES LTD 115
- 13.4.1 COMPANY SNAPSHOT 115
- 13.4.2 REVENUE ANALYSIS 115
- 13.4.3 PRODUCT PORTFOLIO 116
- 13.4.4 RECENT DEVELOPMENT 116
13.5 FAREVA 117
- 13.5.1 COMPANY SNAPSHOT 117
- 13.5.2 PRODUCT PORTFOLIO 117
- 13.5.3 RECENT DEVELOPMENT 117
13.6 HIKMA PHARMACEUTICALS PLC 118
- 13.6.1 COMPANY SNAPSHOT 118
- 13.6.2 REVENUE ANALYSIS 118
- 13.6.3 PRODUCT PORTFOLIO 119
- 13.6.4 RECENT DEVELOPMENTS 119
13.7 INNOVEXIA LIFESCIENCES PVT LTD 121
- 13.7.1 COMPANY SNAPSHOT 121
- 13.7.2 PRODUCT PORTFOLIO 121
- 13.7.3 RECENT DEVELOPMENT 121
13.8 MEDLOCK HEALTHCARE 122
- 13.8.1 COMPANY SNAPSHOT 122
- 13.8.2 PRODUCT PORTFOLIO 122
- 13.8.3 RECENT DEVELOPMENT 122
13.9 RECIPHARM AB. 123
- 13.9.1 COMPANY SNAPSHOT 123
- 13.9.2 PRODUCT PORTFOLIO 123
- 13.9.3 RECENT DEVELOPMENT 123
13.10 SWISSCHEM 124
- 13.10.1 COMPANY SNAPSHOT 124
- 13.10.2 PRODUCT PORTFOLIO 124
- 13.10.3 RECENT DEVELOPMENT 124
13.11 TEVA PHARMACEUTICAL INDUSTRIES LTD 125
- 13.11.1 COMPANY SNAPSHOT 125
- 13.11.2 REVENUE ANALYSIS 125
- 13.11.3 PRODUCT PORTFOLIO 126
- 13.11.4 RECENT DEVELOPMENT 126
13.12 VENUS PHARMA GMBH. 127
- 13.12.1 COMPANY SNAPSHOT 127
- 13.12.2 PRODUCT PORTFOLIO 127
- 13.12.3 RECENT DEVELOPMENT 127
13.13 ZYDUS GROUP 128
- 13.13.1 COMPANY SNAPSHOT 128
- 13.13.2 REVENUE ANALYSIS 128
- 13.13.3 PRODUCT PORTFOLIO 129
- 13.13.4 RECENT DEVELOPMENT 130

14 COMPANY PROFILES (DISTRIBUTORS) 131

14.1 AAH PHARMACEUTICALS LTD 131
- 14.1.1 COMPANY SNAPSHOT 131
- 14.1.2 PRODUCT DESCRIPTION 131
- 14.1.3 RECENT DEVELOPMENT 131
14.2 HENRY SCHEIN, INC. 132
- 14.2.1 COMPANY SNAPSHOT 132
- 14.2.2 REVENUE ANALYSIS 132
- 14.2.3 PRODUCT PORTFOLIO 133
- 14.2.4 RECENT DEVELOPMENT 133
14.3 MAWDSLEYS - BROOKS & CO. LTD. 134
- 14.3.1 COMPANY SNAPSHOT 134
- 14.3.2 PRODUCT DESCRIPTION 134
- 14.3.3 RECENT DEVELOPMENT 134
14.4 MEDLINE INDUSTRIES, LP. 135
- 14.4.1 COMPANY SNAPSHOT 135
- 14.4.2 PRODUCT PORTFOLIO 135
- 14.4.3 RECENT DEVELOPMENT 135

15 COMPANY PROFILES (GENERIC MANUFACTURERS) 136

15.1 FRESENIUS SE & CO. KGAA 136
- 15.1.1 COMPANY SNAPSHOT 136
- 15.1.2 REVENUE ANALYSIS 136
- 15.1.3 PRODUCT PORTFOLIO 137
- 15.1.4 RECENT DEVELOPMENT 137
15.2 AMNEAL PHARMACEUTICALS LLC 138
- 15.2.1 COMPANY SNAPSHOT 138
- 15.2.2 REVENUE ANALYSIS 138
- 15.2.3 PRODUCT PORTFOLIO 139
- 15.2.4 RECENT DEVELOPMENT 139
15.3 SUN PHARMACEUTICAL INDUSTRIES LTD. 140
- 15.3.1 COMPANY SNAPSHOT 140
- 15.3.2 REVENUE ANALYSIS 140
- 15.3.3 PRODUCT PORTFOLIO 141
- 15.3.4 RECENT DEVELOPMENT 141
15.4 LUPIN. 143
- 15.4.1 COMPANY SNAPSHOT 143
- 15.4.2 REVENUE ANALYSIS 144
- 15.4.3 PRODUCT PORTFOLIO 144
- 15.4.4 RECENT DEVELOPMENT 145
15.5 ZYDUS GROUP 146
- 15.5.1 COMPANY SNAPSHOT 146
- 15.5.2 REVENUE ANALYSIS 146
- 15.5.3 PRODUCT PORTFOLIO 147
- 15.5.4 RECENT DEVELOPMENT 148
15.6 AUROBINDO PHARMA. 149
- 15.6.1 COMPANY SNAPSHOT 149
- 15.6.2 REVENUE ANALYSIS 149
- 15.6.3 PRODUCT PORTFOLIO 150
- 15.6.4 RECENT DEVELOPMENTS 150
15.7 CIPLA INC. 151
- 15.7.1 COMPANY SNAPSHOT 151
- 15.7.2 REVENUE ANALYSIS 151
- 15.7.3 PRODUCT PORTFOLIO 152
- 15.7.4 RECENT DEVELOPMENTS 152
15.8 CONCORD BIOTECH. 153
- 15.8.1 COMPANY SNAPSHOT 153
- 15.8.2 REVENUE ANALYSIS 153
- 15.8.3 PRODUCT PORTFOLIO 154
- 15.8.4 RECENT DEVELOPMENT 154
15.9 DR. REDDY'S LABORATORIES LTD 155
- 15.9.1 COMPANY SNAPSHOT 155
- 15.9.2 REVENUE ANALYSIS 155
- 15.9.3 PRODUCT PORTFOLIO 156
- 15.9.4 RECENT DEVELOPMENT 156
15.10 GLAND PHARMA LIMITED 157
- 15.10.1 COMPANY SNAPSHOT 157
- 15.10.2 SOURCE: COMPANY WEBSITE, ANNUAL REPORTS, AND SEC FILING 157
- 15.10.3 REVENUE ANALYSIS 157
- 15.10.4 PRODUCT PORTFOLIO 158
- 15.10.5 RECENT DEVELOPMENT 158
15.11 GLENMARK PHARMACEUTICALS LTD 159
- 15.11.1 COMPANY SNAPSHOT 159
- 15.11.2 REVENUE ANALYSIS 159
- 15.11.3 PRODUCT PORTFOLIO 160
- 15.11.4 RECENT DEVELOPMENT 160
15.12 HIKMA PHARMACEUTICALS PLC 161
- 15.12.1 COMPANY SNAPSHOT 161
- 15.12.2 REVENUE ANALYSIS 161
- 15.12.3 PRODUCT PORTFOLIO 162
- 15.12.4 RECENT DEVELOPMENTS 162
15.13 INTAS PHARMACEUTICALS LTD. 164
- 15.13.1 COMPANY SNAPSHOT 164
- 15.13.2 PRODUCT PORTFOLIO 164
- 15.13.3 RECENT DEVELOPMENT 164
15.14 PAR PHARMACEUTICAL. 165
- 15.14.1 COMPANY SNAPSHOT 165
- 15.14.2 PRODUCT PORTFOLIO 165
- 15.14.3 RECENT DEVELOPMENT 165
15.15 SANDOZ GROUP AG 166
- 15.15.1 COMPANY SNAPSHOT 166
- 15.15.2 REVENUE ANALYSIS 166
- 15.15.3 PRODUCT PORTFOLIO 167
- 15.15.4 RECENT DEVELOPMENT 167
15.16 SANOFI 168
- 15.16.1 COMPANY SNAPSHOT 168
- 15.16.2 REVENUE ANALYSIS 168
- 15.16.3 PRODUCT PORTFOLIO 169
- 15.16.4 RECENT DEVELOPMENT 169
15.17 VIATRIS INC. 170
- 15.17.1 COMPANY SNAPSHOT 170
- 15.17.2 REVENUE ANALYSIS 171
- 15.17.3 PRODUCT PORTFOLIO 171
- 15.17.4 RECENT DEVELOPMENT 172

16 QUESTIONNAIRE 173

17 RELATED REPORTS 176

18 REFERENCES 177

LIST OF TABLES

TABLE 1 INDIA GENERIC INJECTABLE MARKET, BY THERAPEUTIC APPLICATION, 2022-2035 (USD MILLION) 69
TABLE 2 EUROPE GENERIC INJECTABLE MARKET, BY THERAPEUTIC APPLICATION, 2022-2035 (USD MILLION) 70
TABLE 3 EUROPE ONCOLOGY IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 70
TABLE 4 EUROPE ONCOLOGY IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 70
TABLE 5 EUROPE CARDIOVASCULAR DISORDERS IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 71
TABLE 6 INDIA CARDIOVASCULAR DISORDERS IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 72
TABLE 7 EUROPE INFECTIOUS DISEASES IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 73
TABLE 8 INDIA INFECTIOUS DISEASES IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 74
TABLE 9 EUROPE PAIN MANAGEMENT IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 75
TABLE 10 INDIA PAIN MANAGEMENT IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 75
TABLE 11 EUROPE METABOLIC DISORDERS (DIABETES) IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 76
TABLE 12 INDIA METABOLIC DISORDERS (DIABETES) IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 76
TABLE 13 EUROPE IMMUNOLOGY IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 77
TABLE 14 INDIA IMMUNOLOGY IN GENERIC INJECTABLE MARKET, BY DRUGS, 2022-2035 (USD MILLION) 77
TABLE 15 EUROPE GENERIC INJECTABLE MARKET, BY BIOSIMILAR DRUGS, 2022-2035 (USD MILLION) 82
TABLE 16 INDIA GENERIC INJECTABLE MARKET, BY BIOSIMILAR DRUGS, 2022-2035 (USD MILLION) 83
TABLE 17 EUROPE GENERIC INJECTABLE MARKET, BY END USER, 2022-2035 (USD MILLION) 93
TABLE 18 INDIA GENERIC INJECTABLE MARKET, BY END USER, 2022-2035 (USD MILLION) 93
TABLE 19 EUROPE GENERIC INJECTABLE MARKET, BY END USER, 2022-2035 (USD MILLION) 94
TABLE 20 INDIA GENERIC INJECTABLE MARKET, BY END USER, 2022-2035 (USD MILLION) 94
TABLE 21 EUROPE GENERIC INJECTABLE MARKET, BY DISTRIBUTION CHANNEL, 2022-2035 (USD MILLION) 103
TABLE 22 INDIA GENERIC INJECTABLE MARKET, BY DISTRIBUTION CHANNEL, 2022-2035 (USD MILLION) 103

LIST OF FIGURES

FIGURE 1 INDIA AND EUROPE GENERIC INJECTABLE MARKET: SEGMENTATION 19
FIGURE 2 INDIA AND EUROPE GENERIC INJECTABLE MARKET: DATA TRIANGULATION 21
FIGURE 3 INDIA GENERIC INJECTABLE MARKET: DROC ANALYSIS 22
FIGURE 4 EUROPE GENERIC INJECTABLE MARKET: DROC ANALYSIS 23
FIGURE 5 INDIA GENERIC INJECTABLE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 24
FIGURE 6 EUROPE GENERIC INJECTABLE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 24
FIGURE 7 INDIA AND EUROPE GENERIC INJECTABLE MARKET: COMPANY RESEARCH ANALYSIS 25
FIGURE 8 EUROPE MULTIVARIATE MODELLING 26
FIGURE 9 INDIA AND EUROPE GENERIC INJECTABLE MARKET: INTERVIEW DEMOGRAPHICS 28
FIGURE 10 INDIA AND EUROPE GENERIC INJECTABLE MARKET: VENDOR SHARE ANALYSIS 29
FIGURE 11 INDIA AND EUROPE GENERIC INJECTABLE MARKET: SEGMENTATION 32
FIGURE 12 ESCALATING INCIDENCE OF CHRONIC DISEASES AND SURGE IN THE DEVELOPMENT AND PRODUCTION OF GENERIC INJECTABLE IS DRIVING THE GROWTH OF THE INDIA GENERIC INJECTABLE MARKET IN THE FORECAST PERIOD OF 2024 TO 2035 33
FIGURE 13 SURGE IN DEVELOPMENT AND PRODUCTION OF GENERIC INJECTABLE DRUGS IS EXPECTED TO DRIVE THE EUROPEAN GENERIC INJECTABLE MARKET IN THE FORECAST PERIOD OF 2024 TO 2035 33
FIGURE 14 ONCOLOGY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE INDIA GENERIC INJECTABLE MARKET IN 2024 AND 2035 34
FIGURE 15 ONCOLOGY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE GENERIC INJECTABLE MARKET IN 2024 AND 2035 34
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE GENERIC INJECATBLE MARKET 42
FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF INDIA GENERIC INJECATBLE MARKET 54
FIGURE 18 EUROPE GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, 2023 64
FIGURE 19 EUROPE GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, 2024-2035 (USD MILLION) 65
FIGURE 20 EUROPE GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, CAGR (2024-2035) 65
FIGURE 21 EUROPE GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE 66
FIGURE 22 INDIA GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, 2023 67
FIGURE 23 INDIA GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, 2024-2035 (USD MILLION) 68
FIGURE 24 INDIA GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, CAGR (2024-2035) 68
FIGURE 25 INDIA GENERIC INJECTABLE MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE 69
FIGURE 26 EUROPE GENERIC INJECTABLE MARKET: BY BIOSIMILAR DRUGS, 2023 79
FIGURE 27 EUROPE GENERIC INJECTABLE MARKET: BY BIOSIMILAR DRUGS, 2024-2035 (USD MILLION) 80
FIGURE 28 INDIA GENERIC INJECTABLE MARKET: BY BIOSIMILAR DRUGS, 2023 81
FIGURE 29 INDIA GENERIC INJECTABLE MARKET: BY BIOSIMILAR DRUGS, 2024-2035 (USD MILLION) 82
FIGURE 30 EUROPE GENERIC INJECTABLE MARKET: BY END USER, 2023 87
FIGURE 31 EUROPE GENERIC INJECTABLE MARKET: BY END USER, 2024-2035 (USD MILLION) 88
FIGURE 32 EUROPE GENERIC INJECTABLE MARKET: BY END USER, CAGR (2024-2035) 88
FIGURE 33 EUROPE GENERIC INJECTABLE MARKET: BY END USER, LIFELINE CURVE 89
FIGURE 34 INDIA GENERIC INJECTABLE MARKET: BY END USER, 2023 90
FIGURE 35 INDIA GENERIC INJECTABLE MARKET: BY END USER, 2024-2035 (USD MILLION) 91
FIGURE 36 INDIA GENERIC INJECTABLE MARKET: BY END USER, CAGR (2024-2035) 91
FIGURE 37 INDIA GENERIC INJECTABLE MARKET: BY END USER, LIFELINE CURVE 92
FIGURE 38 EUROPE GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, 2023 97
FIGURE 39 EUROPE GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, 2024-2035 (USD MILLION) 98
FIGURE 40 EUROPE GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2035) 98
FIGURE 41 EUROPE GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 99
FIGURE 42 INDIA GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, 2023 100
FIGURE 43 INDIA GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, 2024-2035 (USD MILLION) 101
FIGURE 44 INDIA GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2035) 101
FIGURE 45 INDIA GENERIC INJECTABLE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 102
FIGURE 46 EUROPE GENERIC INJECTABLE MARKET: COMPANY SHARE 2023 (%) 105
FIGURE 47 INDIA GENERIC INJECTABLE MARKET: COMPANY SHARE 2023 (%) 106